<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775748</url>
  </required_header>
  <id_info>
    <org_study_id>H-31937</org_study_id>
    <nct_id>NCT01775748</nct_id>
  </id_info>
  <brief_title>Effect of Concord Grape Juice on Endothelial Function</brief_title>
  <official_title>Effect Of Concord Grape Juice On Endothelial Function In Obese And Overweight Individuals Over Age 50</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Welch's, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare Concord grape juice to a beverage that contains no grape flavonoids,
      but has a similar appearance and taste (placebo juice). A total of 60 overweight and obese
      participants over age 50 will be enrolled. Each participant will drink each beverage for 4
      weeks with a 2-week rest period between two beverage consumption periods. The order of
      beverages (grape juice first or placebo juice first) will be randomized. The investigators
      will use ultrasound to measure brachial artery flow-mediated dilation, a measure of
      endothelial vasodilator function. The investigators will also collect blood samples to
      further assess the cardiovascular effects of grape juice.

      The aim of the study is to determine whether Concord grape juice improves endothelial
      function in patients at risk who do not have cardiovascular disease and may provide
      information that would guide dietary recommendations. The results may also be used by the
      sponsor to substantiate claims and labeling of their product.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Brachial artery flow mediated dilation</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endothelial function will be assessed as brachial artery flow-mediated dilation using vascular ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nitroglycerin-mediated dilation</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-endothelium-dependent dilation will be assessed by measuring the dilator response to sublingual nitroglycerin using vascular ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-Femoral Pulse Wave Velocity</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Central aortic stiffness will be assessed as carotid-femoral pulse wave velocity using applanation tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use vascular ultrasound to determine maximal hyperemic flow velocity in the brachial artery induced by 4-minute cuff occlusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting glucose and insulin</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting glucose and insulin</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Concord Grape Juice 12 oz per day</intervention_name>
    <description>Grape Juice 12 oz per day</description>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Grape Juice 12 oz per day</intervention_name>
    <description>Placebo Grape Juice 12 oz per day</description>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index ≥ 25 and &lt; 40 kg/m2

          -  Age ≥ 50 years

          -  Otherwise healthy

        Exclusion Criteria:

          -  Clinical diagnosis of atherosclerotic vascular disease.

          -  Clinical history of diabetes mellitus or fasting glucose ≥126 mg/dl

          -  Uncontrolled hypertension

          -  Treatment with an investigational new drug within the last 30 days

          -  Clinical history of other major illness including end-stage cancer, renal failure,
             hepatic failure, or other conditions that in the opinion of the principal
             investigator make the study inappropriate

          -  Psychological illness or condition such as to interfere with the subject's ability to
             understand the requirements of the study

          -  Use of Vitamin E, Vitamin C, beta carotene, lipoic acid, or other food or herbal
             supplements within 1 month of enrollment. Subjects taking multivitamins or other
             forms of vitamin E and C in doses that do not exceed two times the recommended daily
             allowance will not be excluded

          -  Extreme dietary habits (i.e. Atkins, very high protein/low carbohydrate, or vegan
             diet
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Vita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert E Eberhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monika Holbrook, MS</last_name>
    <email>monica.holbrook@bmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Holbrook, MS</last_name>
      <email>monica.holbrook@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Eberhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph A Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
